BPA Call 36E79720A0007-36C24121N0088

The Department of Veterans Affairs, Veterans Integrated Service Network 1, awarded a Blanket Purchase Agreement (BPA) call contract to Otsuka America Pharmaceutical Inc. on October 15, 2020, with a ceiling value of $113,303.91 and a completion date of October 14, 2021. This firm fixed-price contract, which does not utilize a set-aside designation, falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract is for medication delivery to VA facilities in Pittsburgh, Pennsylvania, and represents a delivery order against Otsuka's larger GSA schedule contract. Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer headquartered in Rockville, Maryland, is a primary supplier of specialty pharmaceuticals to the VA, with particular expertise in complex medical conditions.

This BPA call is part of Otsuka's broader relationship with the Veterans Health Administration, which includes a master Blanket Purchase Agreement valued at approximately $83.3 million for Jynarque (tolvaptan), a specialized medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The company's federal supply schedule contract demonstrates its established capability to supply critical pharmaceutical treatments to veteran populations across multiple VA Integrated Service Networks. The delivery order structure enables VA healthcare facilities to efficiently procure medications through streamlined procurement processes, supporting the agency's mission of providing comprehensive specialized pharmaceutical care to veterans nationwide.